<DOC>
	<DOCNO>NCT00585611</DOCNO>
	<brief_summary>The study design define underlie vascular abnormality present patient diastolic heart failure test effect therapy aim vascular abnormality . This study design investigate effect therapy atorvastatin subject diastolic heart failure improve abnormality vascular myocardial structure function , particular emphasis arterial stiffness endothelial dysfunction .</brief_summary>
	<brief_title>Effects Statin Therapy Vascular Properties Outcomes Diastolic Heart Failure Patients</brief_title>
	<detailed_description>Forty subject give either drug ( atorvastatin 40 mg ) placebo randomize fashion daily six month . Using echocardiography , tonometry , flow mediate dilation conduit artery arteriole , baseline cardiovascular anatomy physiology define . Subjects enroll study require come 5 study visit . The initial visit screen visit ; subject consent obtain echocardiogram perform well blood test . At randomization visit ( 4-14 day follow screening ) , subject provide drug placebo blind fashion.Also visit , subject ask 6 minute walk , QOL questionnaire , vascular function test . There follow-up study visit 1 3 month follow randomization . At follow-up visit medical history , pill count brief physical examination perform , repeat QOL questionnaire administer , blood test assess safety statin therapy . At 6 month , final study visit occur . At visit full history detailed physical examination perform . Repeat echocardiogram , 6 minute walk test , QOL questionnaire , vascular function examination perform .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Signed informed consent , Age &gt; 18 , Ejection fraction â‰¥ 50 % , hospitalization heart failure last 6 month current NYHA Class IIIV symptom , OR current NYHA Class IIIIV symptoms one following : 1 . ECG echocardiographic evidence moderate/severe leave ventricular hypertrophy , 2. chest xray evidence pulmonary congestion Probable alternative cause symptom ( pulmonary disease , severe anemia , etc . ) Prior document LVEF &lt; 40 % qualitative moderate great LV systolic dysfunction . Current indication statin therapy Intolerance statin therapy . Documented ischemic heart disease require lipidlowering therapy ( i.e . CAD , myocardial infarction , stroke ) Evidence significant myocardial ischemia stress test screen visit . Evidence hepatic abnormality ( define liver enzymes &gt; 2 time upper limit normal value ) . Uncontrolled hypertension ( BP &gt; 150/100 ) Significant valvular disease . Atrial fibrillation Known familial hypertrophic cardiomyopathy obstructive hypertrophic cardiomyopathy . Restrictive cardiomyopathy systemic illness know associated infiltrative heart disease ( i.e . amyloidosis , sarcoidosis , hemochromatosis ) . Cor pulmonale cause right heart failure relate LV dysfunction . Clinically significant pulmonary disease . Pericardial constriction hemodynamically significant pleural effusion . Uncontrolled arrhythmia . Any systemic condition heart failure may limit survival less 2 year . Advance renal disease ( serum creatinine &gt; 3.0 mg/dl dialysis ) Known intolerance allergy HMG CoA reductase inhibitor Uncontrolled hyper hypothyroidism . Any subject characteristic may interfere study compliance , baseline dementia , substance abuse , history noncompliance medication appointment . Prisoners vulnerable population . Any woman childbearing age document positive pregnancy test . Subject receive therapy investigational therapy participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Heart Failure , Congestive</keyword>
</DOC>